

pEF1/myc-His A, B, and C

Catalog no. V921-20

Rev. date: 7 June 2010 Manual part no. 25-0227

MAN0000071

Table of Contents

| Kit Contents and Storage | iv |
|---------------------------------------|----|
| Introduction | |
| Product Overview | 1 |
| Methods | 2 |
| Cloning into pEF1/myc-His A, B, and C | |
| Transfection and Analysis | |
| Creating Stable Cell Lines | |
| Appendix | 10 |
| Human EF-1α Promoter | 10 |
| pEF1/myc-His Vector | 11 |
| pEF1/myc-His/lacZ | |
| Recipe | |
| Accessory Products | 15 |
| Technical Support | 16 |
| Purchaser Notification | 17 |
| References | 18 |

Kit Contents and Storage

Shipping and Storage

pEF1/myc-His vectors are shipped on wet ice. Upon receipt, store vectors at -20°C.

Kit Contents

All vectors are supplied as detailed below. **Store the vectors at -20°C.**

| Vector | Composition | Amount |
|--------------------------|--|--------|
| pEF1/myc-His A, B, and C | $40~\mu L$ of $0.5~\mu g/\mu L$ vector in $10~mM$ TrisHCl, $1~mM$ EDTA, pH 8.0 | 20 μg |
| pEF1/myc-His/lacZ | $40~\mu L$ of 0.5 $\mu g/\mu L$ vector in 10 mM TrisHCl, 1 mM EDTA, pH 8.0 | 20 μg |

Intended Use

For research use only. Not intended for human or animal diagnostic or therapeutic uses.

Introduction

Product Overview

Description of the System

pEF1/myc-His A, B, and C are 6.2 kb vectors derived from pcDNA[™]3.1/myc-His and designed for overproduction of recombinant proteins in mammalian cell lines. Features of the vectors allow purification and detection of expressed proteins (see pages 11–12 for more information). High-level stable and transient expression can be carried out in most mammalian cells. The vectors contain the following elements:

- Human elongation factor 1α -subunit (hEF- 1α) promoter for high-level expression across a broad range of species and cell types (Goldman *et al.*, 1996; Mizushima and Nagata, 1990) (see page 10 for more information).
- Three reading frames to facilitate in-frame cloning with a C-terminal tag encoding the *myc* (*c-myc*) epitope and a polyhistidine metal-binding peptide.
- Neomycin resistance gene for selection of stable cell lines.
- Episomal replication in cell lines that are latently infected with SV40 or that express the SV40 large T antigen (e.g., COS7).

The control plasmid, pEF1/*myc*-His/*lacZ*, is included for use as a positive control for transfection, expression, and detection in the cell line of choice.

Experimental Outline

Use the following outline to clone and express your gene of interest using pEF1/*myc*-His.

- 1. Consult the multiple cloning sites described on pages 3–5 to determine which vector (A, B, or C) should be used to clone your gene in-frame with the C-terminal *myc* epitope and the polyhistidine tag.
- 2. Ligate your insert into the appropriate vector and transform into *E. coli*. Select transformants on 50 to $100 \mu g/mL$ ampicillin.
- 3. Analyze your transformants for the presence of insert by restriction digestion.
- 4. Select a transformant with the correct restriction pattern and use sequencing to confirm that your gene is cloned in-frame with the C-terminal peptide.
- 5. Transfect your construct into the cell line of choice using your own method of transfection.
- 6. Test for expression of your recombinant gene by western blot analysis or functional assay (for antibodies to the *myc* epitope or the polyhistidine, C-terminal tag, see page 15).
- 7. To purify your recombinant protein, you may use metal-chelating resin such as ProBond™. ProBond™ resin is available separately (see page 15 for ordering information).

Methods

Cloning into pEF1/myc-His A, B, and C

General Molecular Biology Techniques

For help with DNA ligations, *E. coli* transformations, restriction enzyme analysis, purification of single-stranded DNA, DNA sequencing, and DNA biochemistry, refer to *Molecular Cloning: A Laboratory Manual* (Sambrook *et al.*, 1989) or *Current Protocols in Molecular Biology* (Ausubel *et al.*, 1994).

E. coli Host

Many *E. coli* strains are suitable for the growth of this vector including TOP10F′, DH5 α , JM109 and INV α F′. We recommend that you propagate vectors containing inserts in *E. coli* strains that are recombination deficient (*rec*A) and endonuclease A deficient (*end*A).

For your convenience, TOP10F' is available as chemically competent or electrocompetent cells from Invitrogen.

Transformation Method

You may use any method of choice for transformation. Chemical transformation is the most convenient for most researchers. Electroporation is the most efficient and the method of choice for large plasmids.

Maintaining pEF1/myc-His

To propagate and maintain the pEF1/myc-His vectors, use a small amount of the supplied 0.5 μ g/ μ L stock solution in TE, pH 8.0 to transform a recA, endA E. coli strain like TOP10F´, DH5 α , JM109, or equivalent. Select transformants on LB plates containing 50–100 μ g/mL ampicillin. Be sure to prepare a glycerol stock of each plasmid for long term storage (see page 5)

Cloning Considerations

Your insert should contain a Kozak consensus sequence with an ATG initiation codon for proper initiation of translation (Kozak, 1987; Kozak 1990). An example of a Kozak consensus sequence is provided below. Other sequences are possible, but the G or A at position –3 and the G at position +4 (shown in bold) illustrates the most commonly occurring sequence with strong consensus. Replacing one of the two bases at these positions provides moderate consensus, while having neither results in weak consensus. The ATG initiation codon is shown underlined.

(G/A)NNATGG

If you wish to express your protein WITHOUT the C-terminal peptide, be sure to include a stop codon.

Cloning into pEF1/myc-His A, B, and C, Continued

Multiple Cloning Site of Version A

Below is the multiple cloning site for pEF1/myc-His A. Restriction sites are labeled to indicate the cleavage site. The boxed nucleotides indicate the variable region. Note that there is a stop codon between the Spe I site and the BstX I site. The multiple cloning site has been confirmed by sequencing and functional testing. For more information on the hEF-1 α promoter, see page 10. The vector sequence of pEF1/myc-His A is available for downloading from www.invitrogen.com or from Technical Support (see page 16).

| | | | | | | | 3´en | d of hEF-1α In | ntron 1 | |
|------|----------------------------------|---|--------------------|--------------------|--------------|----------------|----------|----------------|-----------------------------|--------------------|
| 1579 | GTTTGGATCT TGG | TTCATTC TCAAGC | CCTCA GAC | CAGTGGTT | CAAAGTT | TTT TTCT | TCCATT | | TCG TGA(f hEF-1α Exor | |
| 1659 | GCTTGGTACT AAT | T7 promoter/priming site ACGACTC ACTATA | GGGA GAC | CCCAAGCT | GGCTAGT | | | AC CGA G | BamHI CT CGG A la Arg | ATC CAC |
| | | BstX I EcoR I | E | EcoR V | BstX I | Not I | | Xb | a I | |
| 1733 | TAG TCC AGT GT *** Ser Ser Va | | TGC AGA Cys Arg | | | | | | | GGG CCC Gly Pro |
| | BstB I | myc epitope | | | | | | Po | lyhistidine tag | I |
| 1799 | TTC GAA CAA AA Phe Glu Gln Ly | A CTC ATC TCA s Leu Ile Ser | | GAT CTG Asp Leu | | | | | | CAC CAT His His |
| | Pme I | | BGH reverse | priming site | | | | | | |
| 1865 | TGA G TTTAAACC | CG CTGATCAGCC | TCGACTGI | GC CTTCT | TAGTTG CO | CAGCCATO | CT GTTG1 | TTTGCC C | CTCCCCC | GT |
| | | | | | BGH polyaden | ylation signal | | | | |
| 1939 | GCCTTCCTTG ACC | CTGGAAG GTGCCA | CTCC CAC | | TCCTAATA | | | TGCATCG | CAT TGT | CTGAGTA |
| | _ | | | | | | | | | |
| | | | | | | | | | | |

Cloning into pEF1/myc-His A, B, and C, Continued

Multiple Cloning Site of Version B

Below is the multiple cloning site for pEF1/myc-His B. Restriction sites are labeled to indicate the cleavage site. The boxed nucleotides indicate the variable region. The multiple cloning site has been confirmed by sequencing and functional testing. For more information on the hEF-1 α promoter, see page 10. The vector sequence of pEF1/myc-His B is available for downloading from www.invitrogen.com or from **Technical Support** (see page 16).

| 1579 | GTTTGGATCT TGGTTCATTC TCAAGCCT | TCA GACAGTGGTT CAAF | | f hEF-1α Intron 1 CAG <u>GTGTCG TGA</u> GGAATTA 5´ end of hEF-1α Exon 2 |
|------|---|--|--|---|
| 1659 | T7 promoter/priming site GCTTGGTACT AATACGACTC ACTATAGG | GGA GACCCAAGCT GGC1 | | 1 1 |
| 1734 | BSTX EcoR AGT CCA GTG TGG TGG AAT TCT GC Ser Pro Val Trp Trp Asn Ser Al | CA GAT ATC CAG CAC | BstXI NotI AGT GGC GGC CGC TCG Ser Gly Gly Arg Ser | |
| 1800 | BstB Imyc epitoCGGTTCGAACAAAAACTCATCTCArgPheGluGlnLysLeuIleSe | CA GAA GAG GAT CTG | | |
| 1866 | Pme I CAT TGA GTTTAAA CCCGCTGATC AGC His *** | BGH reverse priming site CCTCGACT GTGCCTTCTA | GTTGCCAGCC ATCTGTT | GTT TGCCCCTCCC |
| 1939 | CCGTGCCTTC CTTGACCCT GAAGGTGCC | | BGH polyadenylation signal | ATTGCATC GCATTGTCTC |
| | | | | |

Cloning into pEF1/myc-His A, B, and C, Continued

Multiple Cloning Site of Version C

Below is the multiple cloning site for pEF1/myc-His C. Restriction sites are labeled to indicate the cleavage site. The boxed nucleotides indicate the variable region. The multiple cloning site has been confirmed by sequencing and functional testing. For more information on the hEF-1 α promoter, see page 10. The vector sequence of pEF1/myc-His C is available for downloading from www.invitrogen.com or from **Technical Support** (see page 16).

| | 3 end of hEF-1a Intron 1 | |
|--------------|--|--|
| 1579 | GTTTGGATCT TGGTTCATTC TCAAGCCTCA GACAGTGGTT CAAAGTTTTT TTCTTCCATT TCAG <u>GTGTCG TGA</u> GGAATTA 5' end of hEF-1a Exon 2 | |
| 1659 | T7 promoter/priming site Asp718 Kpn BamH Spe GCTTGGTACT AATACGACTC ACTATAGGGA GACCCAAGCT GGCTAG TTA AGC TTG GTA CCG AGC TCG GAT CCA Leu Ser Leu Val Pro Ser Ser Asp Pro | |
| 1732 | BStX EcoR V BStX Not BStE BStB CTA GTC CAG TGT GGT GGA ATT CTG CAG ATA TCC AGC ACA GTG GCG GCC GCT CGA GGT CAC CCA TTC Leu Val Gln Cys Gly Gly Ile Leu Gln Ile Ser Ser Thr Val Ala Ala Ala Arg Gly His Pro Phe | |
| | | |
| | myc epitope Polyhistidine tag | |
| 1798 | myc epitope Polyhistidine tag GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT ATG CAT ACC GGT CAT CAT CAC CAT TGA Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Met His Thr Gly His His His His His His *** | |
| 1798 | GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT ATG CAT ACC GGT CAT CAC CAT CAC CAT TGA Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Met His Thr Gly His His His His His *** | |
| 1798 1864 | GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT ATG CAT ACC GGT CAT CAC CAT CAC CAT TGA Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Met His Thr Gly His His His His His *** | |
| | GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT ATG CAT ACC GGT CAT CAC CAT CAC CAT TGA Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Met His Thr Gly His His His His His *** PmeI BGH reverse priming site | |

E. coli Transformation

Transform your ligation mixtures into a competent recA, endA E. coli strain (e.g., TOP10F′, DH5 α) and select on LB plates containing 50–100 μ g/mL ampicillin. Select 10–20 clones and analyze for the presence and orientation of your insert.



Preparing a Glycerol Stock

We recommend that you sequence your construct with the T7 Promoter Primer and BGH Reverse primer sequences to confirm that your gene is fused in frame with the *myc* epitope and the C-terminal polyhistidine tag. Refer to the diagram on the previous pages for the sequence and location of the primer binding sites. For ordering primers, see page 15.

Once you have identified the correct clone, be sure to purify the colony and make a glycerol stock for long-term storage. Maintain DNA stock of your plasmid at -20° C.

- 1. Streak the original colony out on an LB plate containing $50 \mu g/mL$ ampicillin. Incubate the plate at $37^{\circ}C$ overnight.
- 2. Isolate a single colony and inoculate into 1–2 mL of LB containing 50 μ g/mL ampicillin.
- 3. Grow the culture to mid-log phase ($OD_{600} = 0.5-0.7$).
- 4. Mix 0.85 mL of culture with 0.15 mL of sterile glycerol and transfer to a cryovial.
- 5. Store at –80°C.

Transfection and Analysis

Introduction

Once you have confirmed that your construct is in the correct orientation and fused in frame with the C-terminal peptide, you are ready to transfect your cell line of choice. We recommend that you include the positive control vector and a mock transfection to evaluate your results.

Plasmid Preparation

Plasmid DNA for transfection into eukaryotic cells must be very clean and free from phenol and sodium chloride. Contaminants will kill the cells, and salt will interfere with lipids, decreasing transfection efficiency. We recommend isolating plasmid DNA using the PureLink $^{\text{\tiny M}}$ HiPure Miniprep Kit or the PureLink $^{\text{\tiny M}}$ HiPure Midiprep Kit (see page 15 for ordering information).

Methods of Transfection

For established cell lines (e.g., HeLa), consult original references or the supplier of your cell line for the optimal method of transfection. It is recommended that you follow exactly the protocol for your cell line. Pay particular attention to medium requirements, when to pass the cells, and at what dilution to split the cells. Further information is provided in *Current Protocols in Molecular Biology*.

Methods for transfection include calcium phosphate (Chen and Okayama, 1987; Wigler *et al.*, 1977), lipid-mediated (Felgner *et al.*, 1989; Felgner and Ringold, 1989) and electroporation (Chu *et al.*, 1987; Shigekawa and Dower, 1988). Invitrogen offers the Lipofectamine[™] 2000 Reagent for mammalian transfection For details, contact **Technical Support** (see page 16) or visit www.invitrogen.com.

Positive Control

pEF1/myc-His/lacZ is provided as a positive control vector for mammalian transfection and expression (see page 13), and may be used to optimize transfection conditions for your cell line. The gene encoding β -galactosidase is expressed in mammalian cells under the control of the hEF-1 α promoter. A successful transfection will result in β -galactosidase expression that can be easily assayed (see below).

Assay for β-galactosidase Activity

You may assay for β -galactosidase expression by activity assay using cell-free lysates (Miller, 1972) or by staining the cells for activity. Invitrogen offers the β -Gal Assay Kit and the β -Gal Staining Kit for fast and easy detection of β -galactosidase expression (see page 15).

Transfection and Analysis, Continued

Detecting Fusion Proteins

Several antibodies are available from Invitrogen to detect expression of your fusion protein from pEF1/*myc*-His (see page 15).

To detect fusion protein by western blot, you need to prepare a cell lysate from transfected cells. We recommend that you perform a time course to optimize expression of the fusion protein (*e.g.*, 24, 48, 72 hours, etc. after transfection). To lyse cells:

- 1. Wash cell monolayers (\sim 10⁶ cells) once with phosphate-buffered saline (PBS).
- 2. Scrape cells into 1 mL PBS and pellet the cells at $1,500 \times g$ for 5 minutes.
- 3. Resuspend in 50 μL Cell Lysis Buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-40, pH 7.8, see Recipe on page 14).
- 4. Incubate cell suspension at 37°C for 10 minutes to lyse the cells.
- 5. Centrifuge the cell lysate at $10,000 \times g$ for 10 minutes to pellet nuclei and transfer the post-nuclear lysate to a fresh tube. Assay the lysate for protein concentration. **Note:** Do not use protein assays utilizing Coomassie Blue or other dyes. NP-40 interferes with the binding of the dye with the protein.
- 6. Add SDS-PAGE sample buffer to a final concentration of 1X and boil the sample for 5 minutes.
- 7. Load 20 μ g of lysate onto an SDS-PAGE gel and electrophorese. Use the appropriate percentage of acrylamide to resolve your fusion protein.



The C-terminal peptide containing the *myc* epitope and the polyhistidine region will add approximately 3 kDa to your protein.

Purification

You will need 5×10^6 to 1×10^7 **transfected** cells for purification of your protein on a 2 mL ProBondTM column (or other metal-chelating column). Refer to the manufacturer's instructions before attempting to purify your fusion protein. To prepare cells for lysis, refer to the protocol on page 9.

Creating Stable Cell Lines

Introduction

The pEF1/*myc*-His vectors contain the neomycin resistance gene to allow for selection of stable cell lines using Geneticin[®]. General information and guidelines are provided below for your convenience.

Geneticin® Activity

Geneticin® blocks protein synthesis in mammalian cells by interfering with ribosomal function. It is an aminoglycoside, similar in structure to neomycin, gentamycin, and kanamycin. Expression of the bacterial aminoglycoside phosphotransferase gene (APH), derived from Tn5, in mammalian cells results in detoxification of Geneticin® (Southern and Berg, 1982).

Geneticin[®] Selection Guidelines

Geneticin[®] is available from Invitrogen (see page 15). Use as follows:

- Prepare Geneticin[®] in a buffered solution (e.g., 100 mM HEPES, pH 7.3).
 Filter-sterilize the solution.
- Freeze at –20°C for long-term storage or store at 4°C for short-term storage.
- Use 100 to 1,000 μg/mL of Geneticin[®] in complete medium.
- Test varying concentrations of Geneticin® on your cell line to determine the concentration that kills your cells (kill curve). Cells differ in their susceptibility to Geneticin®. Typically, concentrations between 100 and 1,000 µg/mL Geneticin® are sufficient to kill the untransfected host cell line.

Possible Sites for Linearization

To obtain stable transfectants, you may choose to linearize your vector before transfection. While linearizing your vector may not improve the efficiency of transfection, it ensures that the vector does not integrate in a way that disrupts the gene of interest. The table below lists unique sites that may be used to linearize your construct prior to transformation. **Other restriction sites are possible.** Be sure that your insert does not contain the restriction enzyme site you wish to use to linearize your vector. **Note that the cleavage site is indicated for versions A, B, and C of pEF1/myc-His.**

| Enzyme | Restriction Site (bp) (A,B,C) | Location | Supplier |
|-----------|----------------------------------|----------------------------|----------------------------|
| Ssp I | 4 | Upstream of EF-1α promoter | Many |
| Aat II | 122 | Upstream of EF-1α promoter | Many |
| Mlu I | 351 | Upstream of EF-1α promoter | Many |
| Eam1105 I | 5379 (A), 5383 (B), 5375 (C) | Ampicillin gene | AGS*, Fermentas, Takara |
| Pvu I | 5749 (A), 5753 (B), 5745 (C) | Ampicillin gene | Many |
| Sca I | 5859 (A), 5863 (B), 5855 (C) | Ampicillin gene | Many |

^{*}Angewandte Gentechnologie Systeme

Creating Stable Cell Lines, Continued

Selecting Stable Integrants

Cells divide once or twice in the presence of lethal doses of Geneticin®, so the effects of the drug take several days to become apparent. Geneticin® resistant colonies can generally be identified in 7 to 10 days with complete selection and expansion in 2 to 4 weeks.

- 1. Transfect your cells using the appropriate protocol for your cell line. Include a sample of untransfected cells as a negative control.
- 2. After transfection, wash the cells once with 1X PBS and add fresh medium to the cells.
- 3. 48 hours after transfection, split the cells into fresh medium containing Geneticin® at the appropriate concentration for your cell line. Split the cells such that they are no more than 25% confluent.
- 4. Change selective medium every 3–4 days until neomycin-resistant colonies are detected (7 to 10 days).
- 5. Pick and expand colonies (1–2 weeks).

Preparing Cells for Lysis

Use the procedure below to prepare cells for lysis prior to purification of your protein on ProBondTM. You will need 5×10^6 to 1×10^7 cells for purification of your protein on a 2 mL ProBondTM column (see the ProBondTM Purification manual).

- 1. Seed cells in five T-75 flasks or 2 to 3 T-175 flasks.
- 2. Grow the cells in selective medium until they are 80–90% confluent.
- 3. Harvest the cells by treating with trypsin-EDTA for 2 to 5 minutes or by scraping the cells in PBS.
- 4. Inactivate the trypsin by diluting with fresh medium (if necessary) and transfer the cells to a sterile microcentrifuge tube.
- 5. Centrifuge the cells at $240 \times g$ for 5 minutes. You may lyse the cells immediately or freeze in liquid nitrogen and store at -80° C until needed.

Lysis of Cells

If you are using ProBond™ resin, refer to the ProBond™ Purification manual for details about sample preparation for chromatography. If you are using another metal-chelating resin, refer to the manufacturer's instruction for recommendations on sample preparation.

Appendix

Human EF-1 α Promoter

Description


The diagram below shows all the features of the EF-1 α promoter used in pEF1/myc-His vectors (Mizushima and Nagata, 1990). Features are marked as per Uetsuki *et al.*, 1989.

| | Г | — 5' end of huma | n EF-1α promoter | | | |
|------|--------------------|--------------------------------------|------------------|------------------------------|-------------------------|----------------------|
| 461 | GGAGTGCCTC | GTGAGGCTCC | GGTGCCCGTC | AGTGGGCAGA | GCGCACATCG | CCCACAGTCC |
| 521 | CCGAGAAGTT | GGGGGGAGGG | GTCGGCAATT | GAACCGGTGC | CTAGAGAAGG | TGGCGCGGG |
| 581 | TATA box | AAGTGATGTC | GTGTACTGGC | TCCGCCTTTT Start of Trans | | GGGGGAGAAC |
| 641 | | TGCAGTAGTC | GCCGTGAACG | TTCTTTTTCG | CAACGGGTTT | GCCGCCAGAA Exon I |
| 701 | | | GGTTCCCGCG | GGCCTGGCCT | CTTTACGGGT | TATGGCCCTT |
| 761 | GCGTGCCTTG | AATTACTTCC | ACCTGGCTGC | AGTACGTGAT | TCTTGATCCC | GAGCTTCGGG |
| 821 | TTGGAAGTGG | GTGGGAGAGT | TCGAGGCCTT | GCGCTTAAGG | AGCCCCTTCG | CCTCGTGCTT |
| 881 | GAGTTGAGGC | CTGGCCTGGG | CGCTGGGGCC | GCCGCGTGCG | AATCTGGTGG | CACCTTCGCG |
| 941 | CCTGTCTCGC | TGCTTTCGAT | AAGTCTCTAG | CCATTTAAAA | TTTTTGATGA | CCTGCTGCGA |
| 1001 | CGCTTTTTT | | | ATGCGGGCCA | AGATCTGCAC | ACTGGTATTT |
| 1061 | CGGTTTTTGG | S _I GGCCG <u>CGGGC</u> | | CCCGTGCGTC | CCAGCGCACA | TGTTCGGCGA |
| 1121 | Sp 1 GGCGGGGCCT | GCGAGCGCGG | CCACCGAGAA | TCGGACGGGG | GTAGTCTCAA | GCTGGCCGGC |
| 1181 | CTGCTCTGGT | GCCTGGCCTC | GCGCCGCCGT | Sp 1 | | 1 GCAAGGCTGG |
| 1241 | CCCGGTCGGC | ACCAGTTGCG | TGAGCGGAAA | GATGGCCGCT | TCCCGGCCCT | GCTGCAGGGA |
| 1301 | GCTCAAAATG | GAGGACGCGG | CGCTCGGGAG | Sp 1 AGCGGGCGGG | TGAGTCACCC | ACACAAAGGA |
| 1361 | AAAGGGCCTT | TCCGTCCTCA | GCCGTCGCTT | Ap 1 CATGTGACTC | CACGGAGTAC | CGGGCGCCGT |
| 1421 | CCAGGCACCT | CGATTAGTTC | TCGAGCTTTT | GGAGTACGTC | GTCTTTAGGT | TGGGGGGAGG |
| 1481 | GGTTTTATGC | GATGGAGTTT | CCCCACACTG | AGTGGGTGGA | GACTGAAGTT | AGGCCAGCTT |
| 1541 | GGCACTTGAT | GTAATTCTCC | TTGGAATTTG | CCCTTTTTGA | | TGGTTCATTC |
| 1601 | TCAAGCCTCA | GACAGTGGTT | CAAAGTTTTT | 3' end of Intro | TCAGGTGTCG 5' end of E | |

pEF1/myc-His Vector

Map of pEF1/ myc-His

The figure below summarizes the features of the pEF1/*myc*-His vectors. The sequences for pEF1/*myc*-His A, B, and C are available for downloading from www.invitrogen.com or from **Technical Support** (see page 16).



pEF1/myc-His Vector, Continued

Features of pEF1/myc-His

pEF1/myc-His A (6165 bp), pEF1/myc-His B (6169 bp), and pEF1/myc-His C (6161 bp) contain the following elements. All features have been functionally tested.

| Feature | Benefit |
|---|--|
| Human elongation factor 1α (hEF- 1α) promoter | Permits overexpression of your recombinant protein in a broad range of mammalian cell types (Goldman <i>et al.</i> , 1996; Mizushima and Nagata, 1990). |
| T7 promoter/priming site | Allows for <i>in vitro</i> transcription in the sense orientation and sequencing through the insert. |
| Multiple cloning site in three reading frames | Allows insertion of your gene and facilitates cloning in frame with the <i>myc</i> epitope and polyhistidine C-terminal tag. |
| <i>myc</i> epitope (Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu) | Allows detection of your recombinant protein with the Anti- <i>myc</i> Antibody or Anti- <i>myc</i> -HRP Antibody (Evan <i>et al.</i> , 1985) (see page 15 for ordering). |
| C-terminal polyhistidine tag | Permits purification of your recombinant protein on metal-chelating resin such as ProBond™. |
| | In addition, the C-terminal polyhistidine tag is the epitope for the Anti-His(C-term) Antibody (Lindner <i>et al.</i> , 1997) and the Anti-His (C-term)-HRP Antibody (see page 15 for ordering). |
| BGH reverse priming site | Permits sequencing through the insert. |
| Bovine growth hormone (BGH) polyadenylation signal | Efficient transcription termination and polyadenylation of mRNA (Goodwin and Rottman, 1992). |
| f1 origin | Allows rescue of single-stranded DNA. |
| SV40 early promoter and origin | Allows efficient, high-level expression of the neomycin resistance gene and episomal replication in cells expressing the SV40 large T antigen. |
| Neomycin (Geneticin®) resistance gene | Selection of stable transfectants in mammalian cells (Southern and Berg, 1982). |
| SV40 polyadenylation signal | Efficient transcription termination and polyadenylation of mRNA. |
| pUC origin | High-copy number replication and growth in <i>E. coli</i> . |
| Ampicillin resistance gene (β-lactamase) | Selection of vector in <i>E. coli</i> . |


pEF1/myc-His/lacZ

Description

pEF1/myc-His/lacZ is a 9,226 bp control vector containing the gene for β-galactosidase. This vector was constructed by ligating a 3,852 bp BamH I-Bsm I fragment containing the EF-1 α promoter from pEF1/V5-His to a 5,374 bp BamH I-Bsm I fragment containing the lacZ gene, myc epitope, polyhistidine tag, and neomycin resistance gene from pcDNA $^{\text{\tiny M}}$ 3.1/myc-His/lacZ.

Map of Control Vector

The figure below summarizes the features of the pEF1/*myc*-His/*lac*Z vector. The nucleotide sequence for pEF1/*myc*-His/*lac*Z is available for downloading from www.invitrogen.com or by contacting **Technical Support** (see page 16).



EF-1 α promoter: bases 468-1653

T7 promoter/priming site: bases 1670-1689

LacZ gene: bases 1770-4826 myc epitope: bases 4851-4880 Polyhistidine tag: bases 4896-4913

BGH reverse priming site: bases 4936-5403 BGH polyadenylation signal: bases 4939-5166

f1 origin: bases 5212-5640

SV40 promoter and origin: bases 5689-5976 Neomycin resistance gene: bases 6051-6845 SV40 polyadenylation signal: bases 7021-7151

pUC origin: bases 7534-8207

Ampicillin resistance gene: 8352-9212

Recipe

Cell Lysis Buffer

50 mM Tris, pH 7.8

150 mM NaĈl

1% Nonidet P-40

1. This solution can be prepared from the following common stock solutions. For 100 mL, combine:

 1 M Tris base
 5 mL

 5 M NaCl
 3 mL

 Nonidet P-40
 1 mL

- 2. Bring the volume up to 90~mL with deionized water and adjust the pH to 7.8~with HCl.
- 3. Bring the volume up to 100 mL. Store at room temperature.

Note: Protease inhibitors may be added at the following concentrations:

1 mM PMSF

1 μg/mL pepstatin

1 μg/mL leupeptin

Accessory Products

Introduction

The following products may be used with the pEF1/*myc*-His vectors. For details, visit www.invitrogen.com or contact **Technical Support** (see page 16).

| Item | Amount | Catalog no. |
|--|---|-------------|
| ProBond™ Purification System | 6 × 2 mL precharged, prepacked ProBond™ resin columns and buffers for native and denaturing purification | K850-01 |
| ProBond™ Resin | 50 mL | R801-01 |
| Trobolia Resili | 150 mL | R801-15 |
| Electrocomp™ TOP10F′ | 5 × 80 μL | C665-55 |
| One Shot® TOP10F′ Chemically Competent <i>E. coli</i> | 20 × 50 μL | C3030-03 |
| PureLink™ HiPure Plasmid Miniprep Kit | 100 preps | K2100-03 |
| PureLink™ HiPure Plasmid Midiprep Kit | 25 preps | K2100-04 |
| β-Gal Assay Kit | 80 mL | K1455-01 |
| β-Gal Staining Kit | 1 kit | K1465-01 |
| | 1 gram | 11811-023 |
| Geneticin® | 5 grams | 11811-031 |
| | 25 grams | 11811-098 |
| Lipofectamine™ 2000 Reagent | 0.75 mL | 11668-027 |

Primers

For your convenience, Invitrogen offers a custom primer synthesis service. Visit www.invitrogen.com for more details.

Antibodies

If you do not have an antibody specific to your protein, Invitrogen offers the Anti-*myc*, or Anti-His(C-term) antibodies to detect your recombinant fusion protein. Horseradish peroxidase (HRP)- and alkaline phosphatase (AP)– conjugated antibodies are available for convenient one-step detection.

| Antibody | Epitope | Catalog no. |
|----------------------|--|-------------|
| Anti-myc | Detects a 10 amino acid epitope | R950-25 |
| Anti-myc-HRP | derived from <i>c-myc</i> (Evan <i>et al.</i> , 1985): | R951-25 |
| Anti-myc-AP | EQKLISEEDL | R952-25 |
| Anti-His(C-term) | Detects the C-terminal polyhistidine | R930-25 |
| Anti-His(C-term)-HRP | tag (requires the free carboxyl group for detection) (Lindner et al., 1997): | R931-25 |
| Anti-His(C-term)-AP | HHHHHH-COOH | R932-25 |

Technical Support

Web Resources



Visit the Invitrogen website at <u>www.invitrogen.com</u> for:

- Technical resources, including manuals, vector maps and sequences, application notes, SDS, FAQs, formulations, citations, handbooks, etc.
- Complete technical support contact information
- Access to the Invitrogen Online Catalog
- Additional product information and special offers

Contact Us

For more information or technical assistance, call, write, fax, or email. Additional international offices are listed on our website (www.invitrogen.com).

Corporate Headquarters:

5791 Van Allen Way Carlsbad, CA 92008 USA Tel: 1 760 603 7200

Tel (Toll Free): 1800 955 6288

Fax: 1 760 602 6500

E-mail: tech support@invitrogen.com

Japanese Headquarters:

LOOP-X Bldg. 6F 3-9-15, Kaigan Minato-ku, Tokyo 108-0022 Tel: 81 3 5730 6509

Fax: 81 3 5730 6519 E-mail: <u>ipinfo@invitrogen.com</u>

European Headquarters:

Inchinnan Business Park 3 Fountain Drive Paisley PA4 9RF, UK Tel: +44 (0) 141 814 6100 Tech Fax: +44 (0) 141 814 6117 E-mail: eurotech@invitrogen.com

SDS

Safety Data Sheets (SDSs) are available on our website at www.invitrogen.com/sds.

Certificate of Analysis

The Certificate of Analysis provides detailed quality control and product qualification information for each product. Certificates of Analysis are available on our website. Go to www.invitrogen.com/support and search for the Certificate of Analysis by product lot number, which is printed on the box.

Limited Warranty

Invitrogen (a part of Life Technologies Corporation) is committed to providing our customers with high-quality goods and services. Our goal is to ensure that every customer is 100% satisfied with our products and our service. If you should have any questions or concerns about an Invitrogen product or service, contact our Technical Support Representatives. All Invitrogen products are warranted to perform according to specifications stated on the certificate of analysis. The Company will replace, free of charge, any product that does not meet those specifications. This warranty limits the Company's liability to only the price of the product. No warranty is granted for products beyond their listed expiration date. No warranty is applicable unless all product components are stored in accordance with instructions. The Company reserves the right to select the method(s) used to analyze a product unless the Company agrees to a specified method in writing prior to acceptance of the order.

Invitrogen makes every effort to ensure the accuracy of its publications, but realizes that the occasional typographical or other error is inevitable. Therefore the Company makes no warranty of any kind regarding the contents of any publications or documentation. If you discover an error in any of our publications, please report it to our Technical Support Representatives.

Life Technologies Corporation shall have no responsibility or liability for any special, incidental, indirect or consequential loss or damage whatsoever. The above limited warranty is sole and exclusive. No other warranty is made, whether expressed or implied, including any warranty of merchantability or fitness for a particular purpose.

Purchaser Notification

Limited Use Label License No. 22: Vectors and Clones Encoding Histidine Hexamer This product is licensed under U.S. Patent Nos. 5,284,933 and 5,310,663 and foreign equivalents from Hoffmann-LaRoche, Inc., Nutley, NJ and/or Hoffmann-LaRoche Ltd., Basel, Switzerland and is provided only for use in research. Information about licenses for commercial use is available from QIAGEN GmbH, Max-Volmer-Str. 4, D-40724 Hilden, Germany.

Limited Use Label License No. 60: EF-1α Promoter EF-1alpha promoter products are sold under license for research purposes only. The use of this product for any commercial purpose, including but not limited to, use in any study for the purpose of a filing of a new drug application, requires a license from: Mochida Pharmaceutical Co., Ltd., 7, Yotsuya 1-Chome, Shinjuku-Ku, Tokyo 160, Japan. Tel: 81-3-3225-5451; Fax: 81-3-3225-6091.

References

- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1994). Current Protocols in Molecular Biology (New York: Greene Publishing Associates and Wiley-Interscience).
- Chen, C., and Okayama, H. (1987). High-Efficiency Transformation of Mammalian Cells by Plasmid DNA. Molec. Cell. Biol. 7, 2745-2752.
- Chu, G., Hayakawa, H., and Berg, P. (1987). Electroporation for the Efficient Transfection of Mammalian Cells with DNA. Nucleic Acids Res. 15, 1311-1326.
- Evan, G. I., Lewis, G. K., Ramsay, G., and Bishop, V. M. (1985). Isolation of Monoclonal Antibodies Specific for *c-myc* Proto-oncogene Product. Mol. Cell. Biol. *5*, 3610-3616.
- Felgner, P. L., Holm, M., and Chan, H. (1989). Cationic Liposome Mediated Transfection. Proc. West. Pharmacol. Soc. 32, 115-121.
- Felgner, P. L., and Ringold, G. M. (1989). Cationic Liposome-Mediated Transfection. Nature 337, 387-388.
- Goldman, L. A., Cutrone, E. C., Kotenko, S. V., Krause, C. D., and Langer, J. A. (1996). Modifications of Vectors pEF-BOS, pcDNA1, and pcDNA3 Result in Improved Convenience and Expression. BioTechniques *21*, 1013-1015.
- Goodwin, E. C., and Rottman, F. M. (1992). The 3´-Flanking Sequence of the Bovine Growth Hormone Gene Contains Novel Elements Required for Efficient and Accurate Polyadenylation. J. Biol. Chem. 267, 16330-16334.
- Kozak, M. (1987). An Analysis of 5´-Noncoding Sequences from 699 Vertebrate Messenger RNAs. Nucleic Acids Res. 15, 8125-8148.
- Kozak, M. (1991). An Analysis of Vertebrate mRNA Sequences: Intimations of Translational Control. J. Cell Biol. 115, 887-903.
- Kozak, M. (1990). Downstream Secondary Structure Facilitates Recognition of Initiator Codons by Eukaryotic Ribosomes. Proc. Natl. Acad. Sci. USA *87*, 8301-8305.
- Lindner, P., Bauer, K., Krebber, A., Nieba, L., Kremmer, E., Krebber, C., Honegger, A., Klinger, B., Mocikat, R., and Pluckthun, A. (1997). Specific Detection of His-tagged Proteins With Recombinant Anti-His Tag scFv-Phosphatase or scFv-Phage Fusions. BioTechniques 22, 140-149.
- Miller, J. H. (1972). Experiments in Molecular Genetics (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory).
- Mizushima, S., and Nagata, S. (1990). pEF-BOS, a Powerful Mammalian Expression Vector. Nucleic Acids Res. 18, 5322.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, Second Edition (Plainview, New York: Cold Spring Harbor Laboratory Press).
- Shigekawa, K., and Dower, W. J. (1988). Electroporation of Eukaryotes and Prokaryotes: A General Approach to the Introduction of Macromolecules into Cells. BioTechniques *6*, 742-751.
- Southern, P. J., and Berg, P. (1982). Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter. J. Molec. Appl. Gen. 1, 327-339.
- Uetsuki, T., Naito, A., Nagata, S., and Kaziro, Y. (1989). Isolation and Characterization of the Human Chromosomal Gene for Polypeptide Chain Elongation Factor-1α. J. Biol. Chem. 264, 5791-5798.
- Wigler, M., Silverstein, S., Lee, L.-S., Pellicer, A., Cheng, Y.-C., and Axel, R. (1977). Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells. Cell 11, 223-232.



Corporate Headquarters

5791 Van Allen Way Carlsbad, CA 92008 T: 1 760 603 7200

F: 1 760 602 6500

E: tech_support@invitrogen.com

For country-specific contact information, visit our web site at **www.invitrogen.com**